Home › Endometrial Cancer › Oklahoma
Endometrial Cancer clinical trials in Oklahoma
30 studies for Endometrial Cancer are looking for participants at sites in Oklahoma.
Cities in Oklahoma
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 2
Ages 18 and older · Women · Updated Nov 12, 2026 · NCT05112601Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 1
Ages 18 and older · Women · Updated Nov 12, 2026 · NCT05950464Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 2
All ages · All sexes · Updated Nov 12, 2026 · NCT05564377Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 2
Ages 18 and older · Women · Updated Nov 12, 2026 · NCT05640999A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
- Peggy & Charles Stephenson Oklahoma Cancer Center, Oklahoma City
RecruitingPhase 3
Ages 18 and older · Women · Updated Nov 10, 2026 · NCT06340568A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- University of Oklahoma Health Sciences Center, Stephenson Cancer Center ( Site 6012), Oklahoma City
- Oklahoma Cancer Specialists and Research Institute, LLC ( Site 6047), Tulsa
RecruitingPhase 3
Ages 18 and older · Women · Updated Nov 10, 2026 · NCT06952504Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 3
Ages 18 and older · Women · Updated Nov 6, 2026 · NCT07198074Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- University of Oklahoma - Health Sciences Center, Oklahoma City
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT05579366Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic
- OU Health Stephenson Cancer Center, Oklahoma City
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 23, 2026 · NCT07807345A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Stephenson Cancer Center, Oklahoma City
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT04657068ALPINE: Maintenance Letrozole/Abemaciclib
- OU Health Stephenson Cancer Center, Oklahoma City
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 15, 2026 · NCT06366347DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Research Site, Oklahoma City
RecruitingPhase 3
Ages 18 and older · Women · Updated Oct 13, 2026 · NCT06989112Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
- University of Oklahoma, Oklahoma City
RecruitingPhase 1
Ages 18 and older · Women · Updated Oct 13, 2026 · NCT06795009Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
- OU Health Stephenson Cancer Center, Oklahoma City
RecruitingPhase 1
Ages 15 and older · All sexes · Updated Oct 9, 2026 · NCT06276491The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- University of Oklahoma, Oklahoma City
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Oklahoma City
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05867251Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- Stephenson Cancer Center, Oklahoma City
RecruitingPhase 1/2
Ages 18 and older · Women · Updated Sep 25, 2026 · NCT03564340Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- University of Oklahoma, Oklahoma City
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06128551A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
- Stephenson Cancer Center at OU Health, Oklahoma City
RecruitingPhase 2
Ages 18 and older · Women · Updated Aug 21, 2026 · NCT05548296A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Oklahoma City
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT07182149A Study of DM002 in Patients With Advanced Solid Tumors
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT06751329A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Stephenson Cancer Center Oklahoma University Health, Oklahoma City
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 29, 2026 · NCT05377996Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
- Mercy Hospital - OKC, Oklahoma City
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jun 29, 2026 · NCT07327489A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
- University of Oklahoma Health Stephenson Cancer Center, Oklahoma City
RecruitingPhase 1/2
Ages 18 and older · Women · Updated Apr 1, 2026 · NCT04486352Uterine Preservation Via Lifestyle Transformation
- University of Oklahoma, Oklahoma City
RecruitingPhase 2
Ages 18 and older · Women · Updated Jan 20, 2026 · NCT05903131A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
- Dren Investigational Site, Oklahoma City
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jan 7, 2026 · NCT06999187Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
- Oklahoma University Stephenson Cancer Center, Oklahoma City
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 13, 2025 · NCT05997017A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
- University of Oklahoma, Oklahoma City
RecruitingPhase 2
Ages 18 to 70 · Women · Updated Oct 30, 2025 · NCT06481592SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Tulsa
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
- Oklahoma Cancer Specialists and Research Institute, Tulsa
RecruitingPhase 2/3
Ages 18 and older · Women · Updated May 2, 2024 · NCT05797831From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.